Page 43 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 43
Joint Workshop: EASL-Public Health CAG Lehar 1 & 2
Chairs:
Alessio Aghemo, Italy
Angelos Hatzakis, Greece
8:00 - 8:15 Efforts to estimate HBV prevalence and future trends SCIENTIFIC PROGRAMME
8:15 - 8:30 Joerdis Ott, Switzerland
8:30 - 8:45 HBV vaccination: A global success story and prospects for
universal coverage
8:45 - 9:00 Alex Vorsters, Belgium
9:00 - 9:15
9:15 - 9:30 Modelling studies to assess the global burden of HCV in the
9:30 - 10:00 next 20 years
10:00 - 10:15 Homie Razavi, The United States
10:15 - 10:30 Current and future HCV burden in Egypt
Imam Waked, Egypte
10:30 - 10:45
10:45 - 11:00 Current and future HCV burden in Greece
Vana Sypsa, Greece
Current and future HCV burden in Germany
Heiner Wedemeyer, Germany
Coffee Break
Current and future options to treat high risk groups and
difficult to treat patients: Chronic HBV
Maurizia Brunetto, Italy
Current and future options to treat high risk groups and
difficult to treat patients: Chronic HCV
Jason Grebely, Australia
Prospects for an effective HCV vaccine
Thomas Baumert, France
Discussion
Vienna, Austria • April 22–26, 2015 43
Chairs:
Alessio Aghemo, Italy
Angelos Hatzakis, Greece
8:00 - 8:15 Efforts to estimate HBV prevalence and future trends SCIENTIFIC PROGRAMME
8:15 - 8:30 Joerdis Ott, Switzerland
8:30 - 8:45 HBV vaccination: A global success story and prospects for
universal coverage
8:45 - 9:00 Alex Vorsters, Belgium
9:00 - 9:15
9:15 - 9:30 Modelling studies to assess the global burden of HCV in the
9:30 - 10:00 next 20 years
10:00 - 10:15 Homie Razavi, The United States
10:15 - 10:30 Current and future HCV burden in Egypt
Imam Waked, Egypte
10:30 - 10:45
10:45 - 11:00 Current and future HCV burden in Greece
Vana Sypsa, Greece
Current and future HCV burden in Germany
Heiner Wedemeyer, Germany
Coffee Break
Current and future options to treat high risk groups and
difficult to treat patients: Chronic HBV
Maurizia Brunetto, Italy
Current and future options to treat high risk groups and
difficult to treat patients: Chronic HCV
Jason Grebely, Australia
Prospects for an effective HCV vaccine
Thomas Baumert, France
Discussion
Vienna, Austria • April 22–26, 2015 43